Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia – real-world analysis of Polish adult leukemia study group

Résumé fourni par la source

We collected clinical data on 363 patients with relapsed/refractory chronic lymphocytic leukemia (RR-CLL) treated with venetoclax-rituximab (VR) in a real-world setting. The median age was 69.5 years (range, 32.5–91.6 years), and the median number of prior lines of therapy was 2 (range, 1–10). Fifty-three recipients (53/362, 13.8%) had previously received BTKi. The median follow-up was 22.8 months. The overall response rate was 97.1%. The median PFS and OS were not reached. The estimated 3 y-PFS rate was 62.1% (95% CI 54.9–70.2), and the 3 y-OS rate was 69.0% (95% CI 62.3–76.4). Eighty-five (23.5%) patients had completed their therapy, while 106 (29.4%) discontinued prematurely. Reasons for therapy discontinuation included mainly patients’ death (n = 36, 34%) and cytopenias (n = 17,16.0%). Treatment outcomes with the VR regimen in a real-life setting were slightly worse than those reported in the MURANO trial, likely due to the inclusion of patients with advanced ECOG and prior BTKi treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.